Top Takeaways:
- Nicotine pouches release dramatically fewer harmful chemicals than cigarettes and many smokeless products, with toxicant levels akin to nicotine gum in lab analyses.
- Early biomarker and clinical studies show lower disease risk for exclusive pouch users—markers for carcinogens, heart disease, inflammation, and lung injury markedly improved versus smokers.
- Evidence remains preliminary and short-term, prompting experts to call for longer-term, independent research before drawing definitive public health conclusions.
A sweeping review of 54 peer‑reviewed studies published in Cureus found nicotine pouch users are exposed to significantly fewer toxicants than cigarette smokers, with early clinical indicators pointing to reduced disease risk. However, researchers stress more long-term, independent research is critical to fully understand the finding’s implications for public health.
Chemical analyses referenced in the review demonstrate that nicotine pouches contain “dramatically reduced” levels of harmful chemicals. In one study, only trace chemicals were detected out of 26 priority toxins, yielding a toxicant profile comparable to regulated nicotine replacement products.
Another lab test found that 20 of 21 pouches had undetectable levels of carcinogens such as benzo[a]pyrene and tobacco‑specific nitrosamines.
Human biomarker studies support these findings. In a Danish and Swedish clinical study, exclusive Velo pouch users showed reductions in seven of eight exposure markers by 23–97% compared to smokers; the lung‑carcinogen metabolite NNAL dropped by 91%.
Markers for heart disease and inflammation—including carboxy‑hemoglobin and white blood cell count—decreased by up to 46%, while exhaled nitric oxide, typically suppressed in smokers, rebounded by 97%. according to a media report.
Nicotine absorption in pouches appears slower and less intense than in cigarettes, peaking when the pouch is removed rather than through rapid lung uptake. This suggests a lower abuse potential.
Behavioral evidence also points to potential benefits. In one six‑week U.S. observational study, 82 of 100 smokers reduced their daily cigarette consumption after introducing Velo pouches, with nearly one‑sixth cutting their intake by more than half.
Survey data further indicate most Zyn users are former or current smokeless tobacco users, and over 60% of smokers and vapers report using pouches to quit or cut back on cigarettes or vaping.
A population-level model estimated that introducing Zyn in 2000 could have prevented approximately 320,000 deaths overall and 700,000 tobacco-related deaths in the U.S. by 2050, even under conservative risk assumptions.
Concerns about youth uptake remain low. A British survey of 25,698 adults in 2021 found current pouch use at just 0.26%, with never‑smokers at 0.06%. U.S. youth surveys reported ever-use below 2% and frequent use under 1% among high schoolers.
Despite these encouraging signs, the review emphasizes limitations. Most studies are brief—lasting weeks or months—and rely on older pouch formulations. Important gaps remain, including long‑term cardiovascular outcomes, flavor-specific toxicity, and durable switching rates beyond half‑a‑year.
Researcher Erika Grandolfo stated: “So far, the sum of the available broader category science… is overwhelmingly positive from a tobacco harm reduction perspective.” Thomas Nahde added that the review found “little evidence nicotine pouches… might serve as a ‘gateway’ to regular nicotine use among nicotine‑naïve populations”
Publicly funded long-term studies are now underway in Europe and the U.S., aiming to generate more definitive data. For now, the consensus from existing evidence is cautiously optimistic: nicotine pouches pose far less risk than continued smoking, though they are not risk-free
In Canada, Zonnic pouches with flavorless and mint options are available by prescription in pharmacies, opening a pathway for regulated harm‑reduction use. The health impact will hinge on how many of Canada’s four million smokers are willing and able to switch.
